drugset / Trial / NCT03054298
CAR T Cells in Mesothelin Expressing Cancers
Phase 1
Completed
65 enrolled
University of Pennsylvania
National Institutes of Health (NIH) · collabTmunity Therapeutics, a wholly owned subsidiary of Kite Pharma (a Gilead company) · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
Phase I study to establish safety and feasibility of both intravenous administration and local delivery of lentiviral transduced huCART-meso cells with or without lymphodepletion.
Timeline
- Start
- 2017-04-06
- Primary completion
- 2023-11-09
- Completion
- 2024-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | huCART-meso cells | Cell therapy | — | Intravenous |